These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3120487)

  • 1. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
    Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A
    Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease--an interim analysis.
    Teychenne PF; Parker S
    Acta Neurol Scand Suppl; 1989; 126():119-25. PubMed ID: 2515717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
    Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
    Heinonen EH; Rinne UK; Tuominen J
    Acta Neurol Scand Suppl; 1989; 126():113-8. PubMed ID: 2515716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W; Birkmayer GD
    J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
    Myllylä VV; Heinonen EH; Vuorinen JA; Kilkku OI; Sotaniemi KA
    Acta Neurol Scand; 1995 Mar; 91(3):177-82. PubMed ID: 7793231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-(-)-deprenyl in the treatment of end-of-dose akinesia.
    Ulm G; Fornadi F
    J Neural Transm Suppl; 1987; 25():163-72. PubMed ID: 3123603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
    Frankel JP; Kempster PA; Stibe CM; Eatough VM; Nathanson M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1989 Oct; 12(5):448-51. PubMed ID: 2514981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 17. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deprenyl (selegiline) in combination treatment of Parkinson's disease.
    Gerstenbrand F; Ransmayr G; Poewe W
    Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline as primary treatment in early phase Parkinson's disease--an interim report.
    Myllylä VV; Sotaniemi KA; Tuominen J; Heinonen EH
    Acta Neurol Scand Suppl; 1989; 126():177-82. PubMed ID: 2515724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.